A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Alexandroupoli, 그리스, 681 00
- 모병
- Uni General Hospital of Alexandroupolis
-
Athens, 그리스, 11528
- 모병
- Alexandra General Hospital of Athens
-
Athens, 그리스, 115 25
- 모병
- 251 Air Force General Hospital
-
Piraeus, 그리스, 18537
- 모병
- Metaxa Cancer Center Hospital Of Piraeus
-
Rio, 그리스, 265 04
- 모병
- General University Hospital of Patras
-
Thessaloniki, 그리스, 54642
- 모병
- Hippokration Hospital
-
Thessaloniki, 그리스, 546 39
- 모병
- Theageneio Cancer Hospital
-
-
-
-
-
Ampang, 말레이시아, 68000
- 모병
- Hospital Ampang
-
George Town, 말레이시아, 10450
- 모병
- Hospital Pulau Pinang
-
Johor Bharu, 말레이시아, 80100
- 모병
- Hospital Sultanah Aminah
-
Kota Kinabalu, 말레이시아, 88586
- 모병
- Hospital Queen Elizabeth
-
Kuching, 말레이시아, 93586
- 모병
- Sarawak General Hospital
-
-
-
-
Arizona
-
Goodyear, Arizona, 미국, 85338
- 모병
- City of Hope Phoenix
-
-
California
-
Beverly Hills, California, 미국, 90211
- 모병
- Beverly Hills Cancer Center (BHCC)
-
Irvine, California, 미국, 92618
- 모병
- City of Hope Orange County Lennar Foundation Cancer Center
-
Palo Alto, California, 미국, 94304
- 모병
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, 미국, 80218
- 모병
- Colorado Blood Cancer Institute
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School Of Medicine
-
-
Ohio
-
Columbus, Ohio, 미국, 43214
- 모병
- Ohio Health Research Institute
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- 모병
- University of Utah Huntsman Cancer Institute
-
-
-
-
-
Falun, 스웨덴, 791 82
- 모병
- Falu Lasarett Medicinkliniken Falun
-
Gothenburg, 스웨덴, 413 45
- 모병
- Sahlgrenska Universitetssjukhuset
-
Lund, 스웨덴, 221 85
- 모병
- Skanes universitetssjukhus
-
Stockholm, 스웨덴, 141 86
- 모병
- Karolinska University Hospital Huddinge
-
Uppsala, 스웨덴, 752 37
- 모병
- Akademiska Sjukhuset
-
-
-
-
-
Barcelona, 스페인, 08041
- 모병
- Hosp. de La Santa Creu I Sant Pau
-
León, 스페인, 24071
- 모병
- Hosp. de Leon
-
Madrid, 스페인, 28046
- 모병
- Hosp. Univ. La Paz
-
Madrid, 스페인, 28055
- 모병
- Hosp. Blua Sanitas Valdebebas
-
Málaga, 스페인, 29010
- 모병
- Hosp Regional Univ de Malaga
-
Pamplona, 스페인, 31008
- 모병
- Hosp. de Navarra
-
Valencia, 스페인, 46017
- 모병
- Hosp. Univ. Dr. Peset
-
-
-
-
-
Buenos Aires, 아르헨티나, C1199ABB
- 모병
- Hospital Italiano de Buenos Aires
-
Buenos Aires, 아르헨티나, C1426ANZ
- 모병
- Instituto Alexander Fleming
-
Buenos Aires, 아르헨티나, C1118
- 모병
- Hospital Aleman
-
Córdoba, 아르헨티나, X5016KEH
- 모병
- Hospital Privado Centro Medico de Cordoba
-
Pilar, 아르헨티나, 1629
- 모병
- Hospital Universitario Austral
-
-
-
-
-
Braga, 포르투갈, 4710 243
- 모병
- Uls Braga - Hosp. Braga
-
Lisbon, 포르투갈, 1099 023
- 모병
- Ipo Lisboa
-
Lisbon, 포르투갈, 1998 018
- 모병
- Hosp. Cuf Descobertas
-
Porto, 포르투갈, 4200 319
- 모병
- Uls Sao Joao - Hosp. Sao Joao
-
Porto, 포르투갈, 4050 342
- 모병
- Uls Santo Antonio - Hosp. Santo Antonio
-
Vila Nova de Gaia, 포르투갈, 4434 502
- 모병
- Uls Gaia Espinho
-
-
-
-
-
Argenteuil, 프랑스, 95107
- 모병
- Centre Hospitalier Victor Dupouy
-
Bayonne, 프랑스, 64100
- 모병
- Centre Hospitalier de la Cote Basque
-
La Tronche, 프랑스, 38700
- 모병
- CHU de Grenoble
-
Le Mans, 프랑스, 72100
- 모병
- Centre de Cancerologie de la Sarthe
-
Nantes, 프랑스, 44000
- 모병
- CHU Nantes - Hotel Dieu
-
Quimper, 프랑스, 29000
- 모병
- Centre Hospitalier de Quimper Cornouaille
-
-
-
-
-
Budapest, 헝가리, 1088
- 모병
- Semmelweis Egyetem
-
Budapest, 헝가리, 1097
- 모병
- Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
-
Budapest, 헝가리, 1122
- 모병
- Orszagos Onkologiai Intezet
-
Pécs, 헝가리, 7624
- 모병
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
Szeged, 헝가리, 6725
- 모병
- Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar
-
-
-
-
-
Bedford Park, 호주, 5042
- 모병
- Flinders Medical Centre
-
Birtinya, 호주, 4575
- 모병
- Sunshine Coast University Hospital
-
Concord, 호주, 2139
- 모병
- Concord Repatriation General Hospital
-
Fitzroy, 호주, 3065
- 모병
- St Vincents Hospital Melbourne
-
Wollongong, 호주, 2500
- 모병
- Wollongong Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
- Have clinical laboratory values meeting the criteria specified in the protocol
Exclusion criteria:
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
- Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
- Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
- Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm A: Tocilizumab + Ramantamig
Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
다른 이름들:
Tocilizumab will be administered as intravenous (IV) injection. |
|
위약 비교기: Arm B: Placebo + Ramantamig
Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
다른 이름들:
Placebo (saline) will be administered as IV injection. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
기간: By the end of Day 28 from first ramantamig dose
|
Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported. |
By the end of Day 28 from first ramantamig dose
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
기간: By the end of Day 28 from first ramantamig dose
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported. |
By the end of Day 28 from first ramantamig dose
|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
기간: Up to 38 months
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
기간: Up to 38 months
|
Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS for All Grades
기간: Up to 38 months
|
Percentage of participants with re-occurrence of CRS for all Grades will be reported. |
Up to 38 months
|
|
Overall Response
기간: Up to 38 months
|
Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria. |
Up to 38 months
|
|
Complete Response (CR) or Better
기간: Up to 38 months
|
CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to 38 months
|
|
Very Good Partial Response (VGPR) or Better
기간: Up to Month 38
|
VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to Month 38
|
|
Duration of Response (DoR)
기간: Up to 38 months
|
DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first. |
Up to 38 months
|
|
Time to Response (TTR)
기간: Up to 38 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response. |
Up to 38 months
|
|
Progression-Free Survival (PFS)
기간: Up to Month 38
|
PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria. |
Up to Month 38
|
|
Time to Subsequent Antimyeloma Therapy
기간: Up to Month 38
|
Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event. |
Up to Month 38
|
|
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
기간: Up to 38 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event. |
Up to 38 months
|
|
Percentage of Participants with Abnormalities in Laboratory Parameters
기간: Up to 38 months
|
Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported. |
Up to 38 months
|
|
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
기간: Up to 38 Months
|
Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported. |
Up to 38 Months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 79635322MMY2002
- 2025-524793-42 (EudraCT 번호)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .